Teva Reports 2017 Full Year and Fourth Quarter Financial Results

Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset

Goldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $25.00) while maintaining a Buy rating following the company's 4Q earnings and meetings with management.

While 2018 guidance came in lower than expected, analyst Jami Rubin believes it helps reset investor expectations and,... More

Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo

Wells Fargo lowered its price target on Teva Pharma (NYSE: TEVA) to $16.50 (from $17.00) while maintaining an Underperform rating.

"We believe the conference call went poorly and reinforced worries about the weak 2018 guidance," analyst David Maris commented.

Lowers FY 2018 EPS to $2.43, which compares to Tevas guidance of $2.25-2.50.

Teva Pharma (TEVA) PT Lowered to $16 at Cowen

Cowen lowered its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $18.00) while maintaining a Market Perform rating.

Analyst Ken Cacciatore commented, "We have updated our model. The bottom-line is with the free cash flow expected to reach $2.6-2.8B this doesn't... More

Teva Pharma (TEVA) Leaving Room for Upside Surprise in EBITDA Guidance - Evercore ISI

Evercore ISI analyt Umer Raffat said Teva Pharma (NYSE: TEVA) EBITDA expectations at $4.7-$5B (vs sell side at $5.3B) leaves a "healthy room in there for surprising to the upside either on more realized cost cuts or on lesser Copaxone erosion."

"Said another... More

Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.93, $0.17 better than the analyst estimate of $0.76. Revenue for the quarter came in at $5.5 billion versus the consensus estimate of $5.31 billion.

GUIDANCE:

Teva Pharma sees FY2018 EPS of $2.25-$2.50, versus the consensus of... More